TapImmune Inc. To Present At 17th Annual Rodman & Renshaw Healthcare Conference

JACKSONVILLE, Fla., Sep. 2, 2015 /PRNewswire/ -- TapImmune, Inc. ( OTCQB: TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, will be featured as a presenting company at the 17th Annual Rodman & Renshaw Global Investment Conference. Sponsored by H.C. Wainwright & Co., LLC., the presentation will take place Wednesday, September 9^th, 3.00-3.25 p.m. EDT in Louis XVI B (2nd floor) at the St Regis Hotel in New York City.

The presentation will be webcast live and will be archived for 90 days. Access is provided through the following link: http://wsw.com/webcast/rrshq25/tpiv.

Dr. John N. Bonfiglio, Board member and Strategic Advisor to TapImmune will present an overall update and will review TapImmune's currently planned Phase ll clinical development program in breast and ovarian cancer.

Glynn Wilson Ph.D., CEO and Chairman of TapImmune said, "We have made significant clinical progress over the past year with the completion of Phase I clinical trials in Her2/neu breast and breast and ovarian cancer.   This conference is an ideal opportunity for TapImmune to provide an update on these trials and our entry into Phase II clinical programs."

For more information and to schedule 1-on-1 meetings, please visit http://www.rodm.com/

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at www.tapimmune.com for details.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

CONTACTS:

TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1(866) 359-7541

PCG Advisory
Kirin M. Smith
Chief Operating Officer
+1(646) 863-6519
Sean Leous
Chief Communications Officer
+1(646) 863-8998

J. Streicher Capital, LLC
Robert Giordano
+1(917) 327-3938

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-inc-to-present-at-17th-annual-rodman--renshaw-healthcare-conference-300136669.html

SOURCE TapImmune Inc.